Biography

Completed Ph.D. in Pharmaceutics with the title “Development of formulation containing herbal drug and bacteria for the treatment of Non-alcoholic fatty liver disease.” Dr. Tanya has the expertise in isolation and characterization of herbal drugs, their analytical development using HPLC and HPTLC. She also has an expertise in various techniques like QbD, dissolution testing, and many more techniques. Her research area also focuses on exploring the role of gut microbiota in various illness.

Publications

• Ralli T, Saifi Z, Chaudhary A, Aeri V, Kohli K. In-silico, in-vitro and ex-vivo evidence of combining silymarin phytopharmaceutical with piperine, and fulvic acid for enhancing its solubility and permeability. Pharmaceutical Development and Technology, 2023.
• Tanya Ralli, Zoya Saifi, Neha Tyagi, Arya Vidyadhari, Vidhu Aeri & Kanchan Kohli. Deciphering the role of gut metabolites in non-alcoholic fatty liver disease. Critical Reviews in Microbiology, 2022.
• Ralli T, Tripathi T, Kalaiselvan V, Tiwari R, Aeri V, Kohli K. Silymarin as a Phyto-pharmaceutical: Isolation, simultaneous quantification of four biomarkers and in-silico anti-inflammatory activity. Chinese Journal of Analytical Chemistry, 2022:100174.
• Ralli T, Saifi Z, Usmani Z, Aeri V, Aqil M, Kohli K. Enhancing the bioavailability of silymarin phytopharmaceutical by using piperine and fulvic acid and simultaneously quantifying three biomarkers in plasma. Current Analytical Chemistry, 2023.
• Ralli T, Neupane YR, Saifi Z, Kohli K. Gut microbiota as an emerging therapeutic avenue for the treatment of non-alcoholic fatty liver disease. Current Pharmaceutical Design, 2021 Jun 25. doi: 10.2174/1389201022666210625141526.

Awards and Achievement

• DST Inspire fellowship for pursuing Ph.D.
• Qualified Government Patent Examination
• Qualified CSIR-NET, UGC NET, GPAT, NIPER, and GATE in Life Sciences and Ecology and Evolution